MayerFishmanMD

Oncology • Tampa, FL

Associate Professor of Medicine, University S Fla College of Medicine

Join to view full profile

Dr. Fishman is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Fishman's full profile

Already have an account?

Office
12902 Usf Magnolia Dr
# Gu
Tampa, FL 33612
Phone+1 813-745-8343

Fax+1 813-745-8494

Education & Training

University of South Florida MorsaniFellowship, Hematology and Medical Oncology, 1997 - 2000
Washington University/B-JH/SLCH ConsortiumResidency, Internal Medicine, 1993 - 1996
University of Maryland School of MedicineClass of 1993

Certifications & Licensure

FL State Medical License 1997 - 2025
American Board of Internal Medicine Internal Medicine
American Board of Internal Medicine Medical Oncology

Awards, Honors, & Recognition

Regional Top Doctor Castle Connolly, 2014

Clinical Trials

A Phase II Trial of Early Medical Adrenalectomy for "D0.5" Prostate Cancer Start of enrollment: 2000 May 01
Terminated
Phase 2
Liposome Encapsulated SN38 (LE-SN38) in Patients With Advanced Cancer Start of enrollment: 2002 Oct 01
Completed
Phase 1
Sequential ATRA Then IL-2 for Modulation of Dendritic Cells and Treatment of Metastatic Renal Cell Cancer Start of enrollment: 2004 Aug 01
Completed
Phase 2
Bevacizumab and Interleukin-2 in Treating Patients With Metastatic Kidney Cancer Start of enrollment: 2005 Mar 01
Completed
Phase 2
PSMA and TARP Peptide Vaccine With Poly IC-LC Adjuvant in HLA-A2 (+) Patients With Elevated PSA After Initial Definitive Treatment Start of enrollment: 2008 Dec 02
Completed
Not Applicable
A Study of ALT-801 in Combination With Cisplatin and Gemcitabine in Muscle Invasive or Metastatic Urothelial Cancer Start of enrollment: 2011 Sep 06
Completed
Phase 1, Phase 2
Oral Lenalidomide and Intravesical BCG for Therapy of Bladder Cancer Start of enrollment: 2011 Nov 30
Completed
Phase 2
PROCLAIM Registry to Evaluate the Treatment Patterns and Clinical Response in Malignancy Start of enrollment: 2011 Aug 01
Completed
Phase I Study of Percutaneous Valrubicin for Upper Tract Urothelial Carcinoma Start of enrollment: 2012 Jul 01
Completed
Phase 1
Interleukin-2 and Pembrolizumab for Metastatic Kidney Cancer Start of enrollment: 2017 Apr 25
Active, not recruiting
Phase 2
Join now to see all

Publications & Presentations

PubMed

38 citations
Active surveillance of metastatic renal cell carcinoma: Results from a prospective observational study (MaRCC)
Michael R. Harrison, Brian A. Costello, Nrupen A. Bhavsar, Ulka N. Vaishampayan, Sumanta K. Pal
Cancer. 2021-07-01
35 citations
Changes in physical functioning and muscle strength in men receiving androgen deprivation therapy for prostate cancer: a controlled comparison
Brian D. Gonzalez, Heather S.L. Jim, Brent J. Small, Steven K. Sutton, Mayer Fishman
Supportive Care in Cancer. 2016-05-01
96 citations
Downstaging and Survival Outcomes Associated With Neoadjuvant Chemotherapy Regimens Among Patients Treated With Cystectomy for Muscle-Invasive Bladder Cancer.
Charles C. Peyton, Dominic H. Tang, Richard R. Reich, Mounsif Azizi, Juan Chipollini
JAMA Oncology. 2018-11-01

Lectures

Overall survivalÂ (OS) by clinical risk category for high dose interleukin-2 (HD IL-2) treated metastatic renal cell cancer (RCC): Data from PROCLAIM.
2018 ASCO Annual Meeting - Chicago, Illinois - 06/2/2018

Press Mentions

Tampa General Hospital Improves Access to Cancer Care and Treatment in the Riverview AreaSeptember 17th, 2021
Combination Axitinib + Pembrolizumab Active Against Renal Cell CarcinomaFebruary 16th, 2018
Impact of Sequencing Targeted Therapies with High-Dose Interleukin-2 Immunotherapy: An Analysis of Outcome and Survival of Patients with Metastatic Renal Cell Carcinoma from an on-Going Observational IL-2 Clinical Trial: PROCLAIM SMFebruary 1st, 2017
Join now to see all